You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

18 search results for: disease progression

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

1 min

Dermatology

Dr. Stephan Weidinger talks about the role of biomarkers and their impact on clinical decision-making.

expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

43 min

Type 2 Inflammation

Drs. Jonathan Spergel, Wanda Phipatanakul, Eric Simpson, Prof. Salvatore Oliva discuss pediatric patient/caregiver burden and multidisciplinary care

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

expert video

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

25 min

Dermatology

This video from the March 2024 ADVENT AD symposium features Dr. Lawrence Eichenfield presenting the systemic burdens of AD in children and the need for early intervention. Dr. Eichenfield also reviews the multidimensional, atopic, and non-atopic burdens associated with AD in pediatric patients. He goes on to discuss evidence on benefits of early intervention and how it may prevent the progression of local and systemic inflammatory processes over time, followed by a brief panel discussion.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region